CHR Chr. Hansen Holding A/S

Interim report September 1, 2017 - May 31, 2018

Interim report September 1, 2017 - May 31, 2018



Company announcement no.11/2018

Report attached

For further information, please contact:

Martin Riise, Head of Investor Relations

Tel:

Helle Rexen, Interim Head of Media Relations

Tel:

About Chr. Hansen

Chr. Hansen is a leading global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. We develop and produce cultures, enzymes, probiotics and natural colors for a rich variety of foods, confectionery, beverages, dietary supplements and even animal feed and plant protection. Our product innovation is based on more than 30,000 microbial strains – we like to refer to them as “good bacteria.” Our solutions enable food manufacturers to produce more with less – while also reducing the use of chemicals and other synthetic additives – which makes our products highly relevant in today’s world. We have been delivering value to our partners – and, ultimately, end consumers worldwide – for more than 140 years. We are proud that more than 1 billion people consume products containing our natural ingredients every day.

Attachment

EN
28/06/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Chr. Hansen Holding A/S

Rune Majlund Dahl
  • Rune Majlund Dahl

Chr. Hansen (No_rec, TP: DKK) - Discontinuing coverage

We have discontinued coverage of Chr. Hansen in light of its combination with Novozymes. Our last published recommendation, target price, and estimates should no longer be relied upon.

 PRESS RELEASE

Completion of the combination between Novozymes and Chr. Hansen

Completion of the combination between Novozymes and Chr. Hansen January 29, 2024 – Company announcement no. 2 Please see attachment. CONTACT INFORMATION Investor Relations Tobias Cornelius Bjorklund Anders Enevoldsen Press Relations Lina Danstrup Attachment

 PRESS RELEASE

All necessary regulatory approvals have been obtained for the combinat...

All necessary regulatory approvals have been obtained for the combination of Novozymes and Chr. Hansen January 26, 2024 – Company announcement no. 1 Please see attachment. Contact information Investor RelationsDisa Tuominen Press RelationsSanne Seyer-Hansen Attachment

Rune Majlund Dahl
  • Rune Majlund Dahl

Chr. Hansen (Hold, TP: DKK582.00) - Down to HOLD, target price raised

We forecast Chr. Hansen to reach the high end of its 2023 guidance of 10–12% organic revenue growth and a 26–27% EBIT margin, but expect the combined entity (Novonesis) to issue a new guidance upon completion of the merger. As Chr. Hansen shareholders are set to receive 1.5236 new B-shares in Novonesis, the changes in our Novozymes model translate into a raised Chr. Hansen target price of DKK582 (536), and we have thus downgraded to HOLD (BUY).

 PRESS RELEASE

Update on the merger approval process for the combination of Novozymes...

Update on the merger approval process for the combination of Novozymes and Chr. Hansen: South Korean merger approval granted December 20, 2023 Please see attachment. Contact information Investor RelationsDisa Tuominen Press RelationsSanne Seyer-Hansen Attachment

ResearchPool Subscriptions

Get the most out of your insights

Get in touch